- Home
- EPR vs VKTX Comparison
EPR vs VKTX Comparison
Compare EPR & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPR
- VKTX
- Stock Information
- Founded
- EPR 1997
- VKTX 2012
- Country
- EPR United States
- VKTX United States
- Employees
- EPR N/A
- VKTX N/A
- Industry
- EPR Real Estate Investment Trusts
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- EPR Real Estate
- VKTX Health Care
- Exchange
- EPR Nasdaq
- VKTX Nasdaq
- Market Cap
- EPR 3.7B
- VKTX 3.4B
- IPO Year
- EPR 1997
- VKTX 2015
- Fundamental
- Price
- EPR $49.47
- VKTX $34.07
- Analyst Decision
- EPR Hold
- VKTX Strong Buy
- Analyst Count
- EPR 12
- VKTX 14
- Target Price
- EPR $47.68
- VKTX $97.29
- AVG Volume (30 Days)
- EPR 585.2K
- VKTX 4.8M
- Earning Date
- EPR 02-26-2025
- VKTX 02-05-2025
- Dividend Yield
- EPR 6.92%
- VKTX N/A
- EPS Growth
- EPR 19.71
- VKTX N/A
- EPS
- EPR 2.32
- VKTX N/A
- Revenue
- EPR $681,717,000.00
- VKTX N/A
- Revenue This Year
- EPR N/A
- VKTX N/A
- Revenue Next Year
- EPR $3.38
- VKTX $986.87
- P/E Ratio
- EPR $21.32
- VKTX N/A
- Revenue Growth
- EPR N/A
- VKTX N/A
- 52 Week Low
- EPR $39.66
- VKTX $28.64
- 52 Week High
- EPR $50.26
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- EPR 67.87
- VKTX 51.41
- Support Level
- EPR $48.19
- VKTX $28.90
- Resistance Level
- EPR $49.26
- VKTX $34.37
- Average True Range (ATR)
- EPR 0.90
- VKTX 2.37
- MACD
- EPR 0.16
- VKTX 0.66
- Stochastic Oscillator
- EPR 92.41
- VKTX 70.06
About EPR EPR Properties
EPR Properties is a real estate investment trust that leases experiential properties in the United States and Canada. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. New investments are determined based on value and opportunity of the respective industry, location quality, and credit quality of tenants. The majority of revenue comes from the Experiential sector.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.